

**PHARMESIS INTERNATIONAL LTD.**  
(the “**Company**”)  
(Incorporated in the Republic of Singapore)  
(Co. Registration No.: 200309641E)

---

**COMPLETION OF THE ACQUISITION OF  
30% OF THE EQUITY INTEREST IN SICHUAN LONGLIFE**

---

*Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company’s circular dated 11 April 2019.*

The Board refers to the announcements made on 31 December 2018, 29 March 2019, 10 April 2019, 26 April 2019, the circular dated 11 April 2019 and the corrigendum to the circular dated 11 April 2019 in relation to the entry by 成都国嘉联合制药有限公司 (Chengdu Kinna Pharmaceutical Co., Ltd) (the “**Purchaser**”), a wholly-owned subsidiary of the Company, into a conditional sale and purchase agreement to acquire 30% of the equity interest in the registered capital of 四川古蔺肝苏药业有限公司 (Sichuan Longlife Pharmaceutical Co., Ltd) (“**Sichuan Longlife**”) from 成都国嘉投资股份有限公司 (Chengdu Kinna Investment Co., Ltd.) (the “**Proposed Acquisition**”).

The Board wishes to announce that the Proposed Acquisition has been completed. Accordingly, the Purchaser’s equity interest in the registered capital of Sichuan Longlife has increased from 51% to 81%.

BY ORDER OF THE BOARD

Wu Xuedan  
Executive Director and Chief Executive Officer

14 May 2019